Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
ZNF385D	rs13093500	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449167764
ZNF385D	rs4334661	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449167770
ZNF385D	rs9310657	T	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele T is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449167803
ZNF385D	rs9310658	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449167809
ZNF385D	rs9819548	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	29407288	1449167815
ZNF385D	rs9824595	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449167821
ZNF385D	rs7653345	A	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele A is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	29407288	1449167797
ZNF385D	rs9873889	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449167827
ZNF385D	rs7616119	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449167785
ZNF385D	rs12630569	G	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	29407288	1449167758
ZNF385D	rs9879065	C	duloxetine	efficacy	yes	Variant was suggestively significant, but did not reach genome-wide significance. Response was defined by >50% decrease in Montgomery-Asberg Depression Rating Scale (MADRS) score at the end of treatment.	Allele C is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	29407288	1449167833
ZNF385D	rs4261893	TT	duloxetine	efficacy	yes	Patients with the TT genotype had a greater % decrease in the Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline as compared to those with the CC or CT genotype. Note that in the initial GWAS analysis, this variant only reached the "suggestive" (p<5E-5) threshold.	Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT.	28696415	1449750780